Sanofi, Denali face trial setback for neuro drug
DNLI Stock | USD 25.16 0.48 1.94% |
Under 70 percent of all Denali Therapeutics' traders are curious in acquiring. The analysis of the overall investor sentiment regarding Denali Therapeutics suggests that a large number of traders are confidant. Denali Therapeutics' investing sentiment shows overall attitude of investors towards Denali Therapeutics.
Denali |
Sanofis experimental therapy DNL788, developed with Denali Therapeutics , fails in second mid-stage trial within months. Read more here.
Read at seekingalpha.com
Denali Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Denali Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Denali Therapeutics Fundamental Analysis
We analyze Denali Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Denali Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Denali Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Denali Therapeutics is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Denali Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Denali Therapeutics stock to make a market-neutral strategy. Peer analysis of Denali Therapeutics could also be used in its relative valuation, which is a method of valuing Denali Therapeutics by comparing valuation metrics with similar companies.
Peers
Denali Therapeutics Related Equities
BGNE | BeiGene | 7.31 | ||||
GLUE | Monte Rosa | 5.93 | ||||
FDMT | 4D Molecular | 4.93 | ||||
APLS | Apellis Pharmaceuticals | 4.63 | ||||
BDTX | Black Diamond | 4.05 | ||||
AKRO | Akero Therapeutics | 3.24 | ||||
PCVX | Vaxcyte | 2.77 | ||||
DAWN | Day One | 1.33 | ||||
LEGN | Legend Biotech | 1.29 | ||||
ASND | Ascendis Pharma | 1.28 | ||||
SWTX | SpringWorks Therapeutics | 1.24 | ||||
STOK | Stoke Therapeutics | 1.19 | ||||
HOWL | Werewolf Therapeutics | 0.51 | ||||
BPMC | Blueprint Medicines | 0.50 | ||||
RVMD | Revolution Medicines | 0.09 | ||||
RNA | Avidity Biosciences | 1.07 | ||||
IKNA | Ikena Oncology | 1.17 | ||||
TVTX | Travere Therapeutics | 1.89 | ||||
DSGN | Design Therapeutics | 2.93 |
Complementary Tools for Denali Stock analysis
When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |